UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE.
Blood. 2013 Oct 24;122(17):2922-4. doi: 10.1182/blood-2013-07-514083.
In this issue of Blood, Rossi et al provide convincing evidence that extends and generalizes the importance of trogocytosis, a process in which effector cells use Fcg receptors to remove Immunoglobulin G (IgG)-chelated antigens from donor cells. Their work suggests that the process may be beneficial in the context of epratuzumab treatment of autoimmune diseases.
在本期《Blood》中，Rossi 等人提供了令人信服的证据，扩展并推广了抗体转移（trogoctosis）的重要性，该过程中效应细胞利用 Fcg 受体从供体细胞上移除 IgG 结合的抗原。他们的工作表明，在依帕珠单抗治疗自身免疫性疾病的情况下，该过程可能是有益的。
